Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
TECENTRIQ (Roche Products Pty Ltd)
Product name
TECENTRIQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
133 working days (255)
Active ingredients
atezolizumab (rch)
Registration type
EOI
Indication
Small cell lung cancer
TECENTRIQ (solution for injection), in combination with carboplatin and etoposide, is now also indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.